Posts Tagged ‘Switzerland’
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million
The Swiss company expects the sale proceeds to resolve its current over-indebtedness position ObsEva SA, a biopharmaceutical company based in Geneva Switzerland, developing novel therapies for women’s health, today announced the sale of all of the Company’s rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million and future milestone payments…
Read MoreOpna Bio Raises $38M in Series A Financing
Opna Bio, an Epalinges, Switzerland and San Francisco, CA-based clinical-stage biopharmaceutical company, raised $38M in Series A funding. The round was led by Longitude Capital and Northpond Ventures, with participation from Menlo Ventures. The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse…
Read MoreClaude Nicollier steps down from his position as CSEM
The former astronaut has spent 16 years as Chairperson of the Board of Directors Effective June 2023, Claude Nicollier will step down from his position as CSEM’s Chairperson of the Board of Directors during its Annual General Meeting. “CSEM is well-prepared for the future, meaning I can pass the baton over next year with…
Read MoreDomo Health and Roche develop a digital health solution to detect the first signs of respiratory infections
Domo Health, a leader in digital health, announced the launch of its clinical study in collaboration with Roche Pharma Suisse SA, that aims to develop a digital health solution detecting hypoventilation and warning signs of respiratory infections. The adoption of new digital health technologies is accelerating globally. Thanks to digital health solutions, it is…
Read MoreNovochizol SA and Alpha Chitin Partner to Produce a Chitosan-Based Polysaccharide
Alpha Chitin will manufacture both Novochizol™ raw materials and Novochizol™-based intermediate products. Alpha Chitin, a French biobased chemistry company (Lacq – Aquitaine) and producer of innovative high-quality chitosans, and Novochizol SA, a Swiss biotech (Monthey – Valais) with a unique chitosan processing technology, today announced the creation of a joint venture to realize the…
Read MoreSOPHiA GENETICS Partners with Microsoft to Accelerate Multimodal Health Data Analysis
The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDM™ health data analysis platform available with Microsoft Azure SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare sector based in Lausanne (Switzerland), is embarking on a multi-year integrated strategic partnership with Microsoft to improve healthcare workflows globally. This investment in…
Read MoreDixi Polytool wins CSEM’s Digital Journey Contest
The company will receive CHF 100,000 in technical support from CSEM to develop a smart factory and a 100% autonomous production chain. Family-owned DIXI Polytool is based in the heart of Switzerland’s watchmaking county, Le Locle in Neuchâtel. Specializing in precision, solid carbide, and diamond cutting tools, the company plans to use CSEM’s knowledge…
Read MoreA UNIGE team reveals how Hepatitis B could be cured
The swiss🇨🇭 researchers have deciphered the precise functioning of a protective mechanism that could lead to a potential post-infection treatment The hepatitis B virus (HBV) is responsible for one of the most serious and common infectious diseases. Transmitted through biological fluids, it attacks the liver cells. The chronic form of the disease can lead…
Read MoreiOnctura, EBAMed and Terapet awarded by the Fongit
Fongit, the Fondation Genevoise pour l’Innovation Technologique, has just announced the latest beneficiaries of the Fongit Innovation Fund (FIF). iOnctura is awarded a growth loan of CHF 400,000. EBAMed and Terapet receive each a seed loan of CHF 100,000. The Fongit Innovation Fund The FIF is the instrument for fostering innovation and the…
Read MoreAlcon buys Aerial Pharmaceutics for $770 million
Ophthalmic devices and Geneva-based Alcon has reached an agreement to acquire North Carolina-based Aerie Pharmaceuticals for $770 million (743.1 million francs). The transaction will strengthen the former Novartis subsidiary’s position in the fields of glaucoma and dry eye. Alcon will acquire Rocklatan (netarsudil and latanoproste) and Rhopressa (netarsudil), which are approved for the reduction…
Read More